Background {#Sec1}
==========

Parkinson's disease (PD) is a progressive neurodegenerative disease affecting approximately 630,000 people in the USA and for which no disease-modifying therapy is currently available. With the ever growing ageing population, this number is projected to almost double to 1.1 million by 2030 \[[@CR1]\].

The Food and Drug Administration (FDA) defines "real world data" as "all data collected from sources outside of traditional clinical trials" and "real world evidence" as "all evidence derived from aggregation and analysis of real world data" \[[@CR2]\]. Such real world evidence reflecting disease progression, treatments and outcomes under conditions of routine clinical practice is a very important resource. It can take a pivotal role to improve the understanding of the underlying disease process \[[@CR3]\], optimize currently available therapies and develop new treatment strategies \[[@CR2], [@CR4]\].

Although the burden of PD and the interest of real world data are well-known \[[@CR5], [@CR6]\], there has not been a literature review to present the overview of longitudinal, real world studies conducted in the USA on PD patients.

There is a need for a comprehensive review to create an integrated view and assist investigators and clinicians to optimize the measurements that best match with their objectives and the already existing data sources \[[@CR4], [@CR7]\]. Such an assessment can be very helpful, to support a future effort to harmonize real world data collection and use the available resources in an optimal way.

The objective of this comprehensive literature review is to systematically identify and describe the longitudinal, real world data sources in PD, and to provide a summary of the key characteristics and the measurements assessed in real world studies, as a part of an effort to mobilize a harmonization process, similar to the one that already takes place in Europe.

Methods {#Sec2}
=======

Search strategy and literature sources {#Sec3}
--------------------------------------

The search was performed on ProQuest. It was based in MEDLINE on Pubmed, in EMBASE and internet key word search between May and August 2016. Related MeSH, EMTREE and key terms were combined. Articles from peer-reviewed journals, conference abstracts and reviews were screened (AT). The search equation terms are detailed in [Appendix 1](#Sec12){ref-type="sec"}.

Study screening and selection {#Sec4}
-----------------------------

We included all studies including patients with a diagnosis of PD based on real world data. We restricted inclusion to only longitudinal, observational cohort studies and registries. The setting was restricted to the USA and the timing of publication in the last 10 years (2006-2016). Cohorts or registries without any publication in the last 10 years were considered as outdated. Exclusion criteria were based on population characteristics: Other diagnosis (e.g. Wolff-Parkinson-White disease or only Parkinsonian syndromes), autopsy data, and studies not focused on patients (e.g. focused on physicians). Moreover, studies without American patients or non-longitudinal studies, such as case-control, were also excluded. Only one main exclusion criterion was reported in the flow chart per excluded study (Fig. [1](#Fig1){ref-type="fig"}). No limits were applied for language.Fig. 1Flowchart

Data extraction {#Sec5}
---------------

In a first step, when a publication allowed the identification of a data source of interest, the detailed information available in the publication was extracted. Information on design and setting, funding, population selection, follow-up and measurements were recorded. This was supplemented and updated via information found with an internet search of the study website, registration sites such as [clinicaltrials.gov](http://clinicaltrials.gov) and investigators / funders' websites. The list of all information captured is available in [Appendix 2](#Sec13){ref-type="sec"}.

In a second step, a classification of measurements was performed for the following dimensions: motor and neurological function, cognition, psychiatric symptoms, activities of daily living, sleep quality, quality of life, autonomic symptoms and other. The "other" dimension gathers some known PD symptoms such as olfaction \[[@CR8]\] not included in the previous main dimensions and more general information such as caregivers' burden measurements. Some dimensions were subdivided in sub dimensions due to their complexity and variety (e.g. Motor and neurological symptoms is sub divided into 4 sub dimensions: global, gait and balance, fine movement and other). This classification was based on the literature \[[@CR4]\] with one adaptation: as very few sensory markers were identified, they were gathered in the "other" category.

Data analysis {#Sec6}
-------------

Data source characteristics were described globally. To address the variability of sources, the description was also performed according to four main characteristics: the completion status (ongoing vs completed); the study population (Parkinson specific data sources vs "generic" data sources including both Parkinsonian patients and patients of other diagnostics); the categories of studies (investigate for motor symptoms, non-motor symptoms, biomarkers, genetics or mixed); and the country (US only vs international sources). Descriptive statistics were reported as absolute frequency and percentages.

Results {#Sec7}
=======

Of 1463 records screened, 84% were excluded based on title and abstract, and 7% after review of the full-text (Fig. [1](#Fig1){ref-type="fig"}). The most frequent exclusion criterion was that studies were not longitudinal. Only 133 (9%) were included in the qualitative analysis. Of these 133 studies, data from 53 different data sources were extracted \[[@CR9]--[@CR61]\]. Only one registry was included with 52 cohorts.

Longitudinal real world sources (Table [1](#Tab1){ref-type="table"}) {#Sec8}
--------------------------------------------------------------------

Forty-two sources (79%) were only in the USA. Three of the 11 international sources were only in North America while the other eight included patients in the USA and Europe, and two also included Asia. Most of the sources included less than 500 PD patients (79%) for more than 5 years (51%). Although most of the sources included information about current medications (81%) and comorbidities (79%); only few collected information on medical imaging (36%), genetics (30%), caregiver' burden (11%) and healthcare costs (2%).Table 1Overview of data sources characteristics (*n* = 53)CharacteristicsIncludedStatusCountryStudy populationAll (*n* = 53)Ongoing (*n* = 16)Completed (*n* = 37)USA (*n* = 42)International (*n* = 11)Parkinson cohort\
(*n* = 25)"Generic" cohort\
(*n* = 28)Size (number of Parkinsonian patients)0-50042 (79)11 (69)31 (84)37 (88)5 (45)22 (88)20 (71)500-10007 (13)4 (25)3 (8)3 (7)4 (36)3 (12)4 (14)\>10004 (8)1 (6)3 (8)2 (5)2 (18)0 (0)4 (14)Duration of follow-up (years)\<26 (11)0 (0)6 (16)4 (10)2 (18)4 (16)2 (7)2-520 (38)4 (25)16 (43)16 (38)4 (36)13 (52)7 (25)≥527 (51)12 (75)15 (41)22 (52)5 (45)8 (32)19 (68)Dimensions assessedMotor and neurological46 (87)12 (75)34 (92)36 (86)10 (91)25 (100)21 (75)Cognition41 (77)13 (81)28 (76)36 (86)5 (45)17 (68)24 (86)Psychiatric symptoms38 (72)10 (63)28 (76)30 (71)8 (73)19 (76)17 (61)Activities of daily living22 (42)6 (38)16 (43)15 (36)7 (64)12 (48)10 (36)Sleep quality11 (21)4 (25)7 (19)5 (12)6 (55)2 (8)9 (32)Quality of life9 (17)4 (25)5 (14)5 (12)4 (36)6 (24)3 (11)Autonomic symptoms7 (13)4 (25)3 (8)3 (7)4 (36)0 (0)7 (25)Other20 (38)9 (56)11 (30)13 (31)7 (64)8 (32)12 (43)Other assessmentsCurrent medications43 (81)13 (81)30 (81)32 (76)11 (100)22 (88)21 (75)Comorbidities42 (79)14 (88)28 (76)31 (74)11 (100)20 (80)22 (79)Medical imaging19 (36)6 (40)13 (34)11 (26)8 (73)6 (24)13 (46)Genetics16 (30)6 (38)10 (27)10 (24)6 (55)3 (12)13 (46)Caregiver burden6 (11)4 (27)2 (5)5 (12)1 (9)4 (16)2 (7)Healthcare costs1 (2)1 (7)0 (0)0 (0)1 (9)1 (4)0 (0)Data are shown as absolute frequency (percentage)

Among the 53 sources, 16 (30%) are still ongoing. There has been an increased availability of genetic information (38% vs 27%) and caregivers' burden data (27% vs 5%) in ongoing versus completed sources, respectively. Moreover, there has been a trend toward larger inclusions and longer durations: comparing ongoing versus completed sources, 31% vs 16% included more than 500 patients and 75% vs 41% have a duration of more than 5 years.

Likewise, US sources were smaller and shorter than international sources (88% vs 45% included less than 500 PD patients, and 52% vs 45% have a duration of more than 5 years). US sources reported more caregiver burden data than international sources (12% vs 9%) but less frequently the other assessments such as medical imaging (26% vs 73%) or genetic information (24% vs 55%).

Sources including only Parkinsonian patients were smaller (12% vs 28% included more than 500 patients) and shorter (32% vs 68% had a duration of more than 5 years) than the "generic" cohorts. Medical imaging (24% vs 46%) and genetics (12% vs 46%) were less assessed in Parkinson's specific than in "generic" cohorts.

The 53 data sources have different objectives. Mainly the sources investigated as their primary objective: non-motor symptoms (32%), then biomarkers (21%), motor symptoms (15%) and genetics (4%). Fifteen sources (28%) investigated several of these points as first objective. The sources investigating the biomarkers as primary objective were large and recent with four sources still ongoing and four sources begun in the last 5 years. In contrast, the sources investigating the motor symptoms as primary objective were small, all with less than 500 patients and with very frequent assessment, on average twice a year.

Measurements in real world studies in PD {#Sec9}
----------------------------------------

The name of each included data source with its main characteristics (Table [2](#Tab2){ref-type="table"}) and its measurements (Table [3](#Tab3){ref-type="table"}) are presented individually. A large number of measurements (*n* = 108) was identified through this literature review and each of the 53 sources had its own unique range of measurements (Table [4](#Tab4){ref-type="table"}). Most of the measurements were cited only once or twice. The distribution of the number of measurements over the different dimensions was not equal with only 3 different to assess autonomic symptoms and 43 to assess cognition.Table 2Overview of data sources characteristics listed in alphabetic order (*n* = 53)NbStudyAcronymIndividuals includedFollow-up duration (y)Planned follow-upMain inclusion criteria1A Longitudinal Observational Follow-up of the PRECEPT Study Cohort^a^PostCEPT5374Post-RCT; under dopaminergic therapy2Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease154Every 2 yearsHemi parkinsonism3Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia465Annually4Arizona Study of Aging and Neurodegenerative DiseaseAZSAND3000ongoing5Ashkenazi Jewish LRRK2 consortium cohortLRRK226111.5Every 12-18 monthsAshkenazi Jewish6Baltimore Longitudinal Study of AgingBLSA10,000?ongoingEvery few years for lifeHealthy7Boston university medical center - University of Alabama Birmingham - Washington University in Saint Louis School of medicine802\>40 years8Central Control of Mobility in AgingCCMA439ongoingAnnuallyElderly (\>65 years); non demented9Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study504AnnuallyLevodopa treatment10Charting the progression of disability in Parkinson disease1712Every 6 months\>40 years; mild to moderate Parkinson's disease11Clinical course in Parkinson's disease with elevated homocysteine972Every 2 years35-90 years without brain surgery or neurologic/psychiatric comorbidity12Clinical Research in Neurology (CRIN) - Emory centerCRIN35811513Comparative utility of the BESTest; mini-BESTest; and brief-BESTest for predicting falls in individuals with Parkinson disease: a cohort studyBESTest801Every 6 monthsWithout neuropsychiatric comorbidities14Comparison of the Agonist Pramipexole With Levodopa on Motor Complications of Parkinson's Disease^a^CALM-PD follow-up3012AnnuallyPost-RCT; under dopaminergic therapy; diagnostic \< 7 years15Contursi kindredCONTURSI210?16Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism^a^DATATOP4036Every 3 monthsEarly phase; postRCT; 30-79 years17Depression in Parkinson's disease6853.9Annually18Dopamine agonist withdrawal syndrome in Parkinson disease^a^DAWS930.25AnnuallyNon demented19Einstein Aging Study (Bronx Aging Study)EAS791ongoingEvery 12 to 18 monthsElderly (\>70 years)20Emergence and evolution of social self-management of Parkinson's disease1203Every 6 monthsNon demented21Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study89100; 6 months; 18 months; 4 years; 6 years; 10 years24-h caregiver; without neuroleptic treatment; without some comorbidities22Harvard Alumni Health Study500,002771962; 1966; 1972; 1988; 1993Harvard students23Health Professionals Follow-up StudyHPFS51,529ongoingBiannuallyMen; healthy; 40-75 years24Honolulu Asia Aging StudyHAAS3741153 times between 1994 and 2001Elderly Japanese-American men25Longitudinal study of normal cognition in Parkinson disease1416Biannual for 4 years and annual afterNormal cognition at baseline26Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson's disease^a^3320 --3 --6 --12 --18 -- 24 monthsAdvanced phase with deep brain stimulation27Loss of ability to work and ability to live independently in Parkinson's disease4951028Major life events and development of major depression in Parkinson's disease patientsPEG study2214AnnuallyNew onset (within 3 years)29Mayo Clinic cohort study of Personality and Aging (including Rochester Epidemiology project)721629.2Historically for life20-69 years30Mayo clinic study of aging (Olmsted county resident) - Rochester Epidemiology project indexing systemMCSA2739ongoing31Molecular Epidemiology of Parkinson's DiseaseMEPD1600ongoing\>40 years32Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling1861.56 months; 18 months33Mood and Subthalamic Nucleus Deep Brain Stimulation^a^MOST911Deep brain stimulation eligible; not demented34Morris K Udall Parkinson's Disease Research Center of Excellence cohort - Veteran affairUdall314ongoingElderly (\>60 years)35National Parkinson Foundation Quality Improvement InitiativeNPF-QII10,000on going36NeuroGenetics Research ConsortiumNGRC3072\>1037Nurses' Health StudyNHS280,000ongoingEvery 2 yearsWomen; healthy; 19-51 years38Oxford Parkinson's Disease CentreOPDC15001.518 months39Parkinson's Associated Risk StudyPARS10,000ongoingElderly (\>60 years)40Parkinson's Disease Biomarkers ProgramPDBP1436ongoingEvidence of response to dopaminergic medication41Parkinson's Disease Research Education and Clinical Center - Parkinson's Genetic Research StudyPADRECCS - PaGeR1880ongoing42Parkinson's disease: increased motor network activity in the absence of movementNMRP124.4Every 2 yearsNon demented; tremor-dominant clinical manifestations; without some comorbidities43Parkinson's Progression bioMarkers InitiativePPMI748ongoingEvery 3 months the first year then every 6 monthsUntreated recently diagnosed44Prospective cohort study of impulse control disorders in Parkinson's diseaseICD-PD1644Non demented45Rate of 6-18Ffluorodopa uptake decline in striatal subregions in Parkinson's disease374Every 1 to 2 years46Religious Order StudyROS\>1100\>7AnnuallyElderly; religious clergy47Rush Memory and Aging ProjectRMAP15565AnnuallyElderly without know dementia48Study of Osteoporotic Fractures (SOF) Research GroupSOF9704\>6Tri-annuallyWomen; Elderly (\>65 years)49The effect of age of onset of PD on risk of dementia4404AnnuallyElderly (\>65 years)50University of California Los Angeles Center for Genes and Environmental in Parkinson's DiseaseUCLA CGEP3635Diagnostic \>3 years51University of Miami Brain Endowment BankUM/BEB150ongoingAnnuallyConsent to donate brain52UPDRS activity of daily living score as a marker of Parkinson's disease progression1626Every 2 years53Washington Heights-Inwood Columbia AgingWHICAP27763.7AnnuallyElderly (\>65 years)Post-RCT = Open label extension after a Randomized Controlled Trial^a^Treatment directed data sources Table 3Overview of data source measurements and of the number of evaluations or assessments applied (*n* = 53)NbStudyMotor and neurologicalCognitionPsychiatryActivities of daily livingSleepQuality of lifeAutonomicOther1A Longitudinal Observational Follow-up of the PRECEPT Study Cohort343100002Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease200000003Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia2141000004Arizona Study of Aging and Neurodegenerative Disease4123010115Ashkenazi Jewish LRRK2 consortium cohort322210116Baltimore Longitudinal Study of Aging023000007Boston university medical center - University of Alabama Birmingham - Washington University in Saint Louis School of medicine911001008Central Control of Mobility in Aging211000009Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study1600000010Charting the progression of disability in parkinson disease9110010011Clinical course in Parkinson's disease with elevated homocysteine1911000012Clinical Research in Neurology (CRIN) - Emory center0100000013Comparative utility of the BESTest; mini-BESTest; and brief-BESTest for predicting falls in individuals with Parkinson disease: a cohort study5000000014Comparison of the Agonist Pramipexole With Levodopa on Motor Complications of Parkinson's Disease3122130015Contursi kindred1111101116Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism2500000017Depression in Parkinson's disease2011000018Dopamine agonist withdrawal syndrome in parkinson disease2141010019Einstein Aging Study (Bronx Aging Study)21110000020Emergence and evolution of social self-management of Parkinson's disease2211040021Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study2110100022Harvard Alumni Health Study0000000023Health Professionals Follow-up Study0000000024Honolulu Asia Aging Study2420101125Longitudinal study of normal cognition in Parkinson disease2621000026Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson's disease2222000027Loss of ability to work and ability to live independently in Parkinson's disease2011000028Major life events and development of major depression in Parkinson's disease patients1220000029Mayo Clinic cohort study of Personality and Aging (including Rochester Epidemiology project)0040000030Mayo clinic study of aging (Olmsted county resident) - Rochester Epidemiology project indexing system11030101131Molecular Epidemiology of Parkinson's Disease1300000032Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling1020000033Mood and Subthalamic Nucleus Deep Brain Stimulation2070000034Morris K Udall Parkinson's Disease Research Center of Excellence cohort - Veteran affair2321010135National Parkinson Foundation Quality Improvement Initiative3200010136NeuroGenetics Research Consortium1110000037Nurses' Health Study0500000038Oxford Parkinson's Disease Centre6321210239Parkinson's Associated Risk Study0020000140Parkinson's Disease Biomarkers Program4361651341Parkinson's Disease Research Education and Clinical Center - Parkinson's Genetic Research Study3101000042Parkinson's disease: increased motor network activity in the absence of movement2100000043Parkinson's progression biomarkers initiative1542201244Prospective cohort study of impulse control disorders in Parkinson's disease2121000045Rate of 6-18Ffluorodopa uptake decline in striatal subregions in Parkinson's disease2100000046Religious Order Study61141000047Rush Memory and Aging Project5131100248Study of Osteoporotic Fractures (SOF) Research Group2110000249The effect of age of onset of PD on risk of dementia1610000050University of California Los Angeles Center for Genes and Environmental in Parkinson's Disease2110000051University of Miami Brain Endowment Bank1001000252UPDRS activity of daily living score as a marker of Parkinson's disease progression1011000053Washington Heights-Inwood Columbia Aging16010000 Table 4Measurements classification and use in data sources (*n* = 108)DimensionMeasurement acronymMeasurement full nameData sources (number and numbering)Motor and neurological (*n* = 46)GlobalH&YHoehn and Yahr(*n* = 30) °1,2,3,4,5,7,9,10,13,14,16,17,18,20,21,25,26,27,31,33,34,35,38,40,41,42,44,45,50,51UPDRS-IIIUnified Parkinson's Disease Rating Scale - motor examination(*n* = 41) °1,2,3,4,5,7,8,10,11,13,14,16,17,18,19,20,21,24,25,26,27,28,30,32,33,34,35,36,38,40,41,42,43,44,45,46,47,49,50,52,53UPDRS-IVUnified Parkinson's Disease Rating Scale - motor complications(*n* = 2) n°1,14Gait and balanceBerg balance test(*n* = 2) n°7,10Flamingo test(*n* = 1) n°38FGAFunctional Gait Assessment(*n* = 2) n°7,10FOGQFreezing of gait questionnaire(*n* = 2) n°7,10Gait speed(*n* = 4) n°7,8,10,46PIGDPostural Instability / Gait Difficulty scale(*n* = 2) n°5,40Tandem gait(*n* = 1) n°48TUGTime Up and Go test(*n* = 6) n°7,10,35,38,40,47Walk test(*n* = 5) n°7,10,46,47,48Fine movementFinger tapping(*n* = 3) n°4,46,47Purdue pegboard test(*n* = 6) n°4,7,10,38,46,47Reaction time(*n* = 1) n°24Unknown(*n* = 1) n°15Cognition (*n* = 41)GlobalACEAddenbrooke's Cognitive Examination(*n* = 1) n°40AD-8Ascertian Dementia 8-item Informant(*n* = 1) n°31BDRSBlessed Dementia Rating Scale(*n* = 2) n°19,53CAMCOGCambridge Cognitive Assessment(*n* = 1) n°49CASICognitive Abilities Screening Instrument(*n* = 1) n°24CDRClinical Dementia Rating scale(*n* = 5) n°3,4,6,19,30,53Clock drawing test(*n* = 1) n°4DRS2Dementia Rating Scale 2(*n* = 6) n°4,19,25,26,34,53HDSHasegawa Dementia Rating Scale(*n* = 1) n°24MDRSMattis Dementia Rating Scale(*n* = 2) n°4,26MMSEMini Mental State Examination(*n* = 30) °1,3,4,5,7,9,10,11,12,14,15,16,18,20,21,24,26,28,31,34,36,37,38,42,44,45,46,47,48,50MoCAMontreal Cognitive Assessment(*n* = 9) n°1,4,5,20,34,38,40,41,43IQCODEInformant Questionnaire on Cognitive Decline in Elderly(*n* = 1) n°24SPMSQShort Portable Mental Status Questionnaire(*n* = 1) n°40TICS-MTelephone Interview Cognitive Status Modified(*n* = 2) n°31,37Attention/ Working memoryDigit span(*n* = 6) n°3,4,11,30,37,46STROOP test(*n* = 2) n°4,11Executive functionComprehension(*n* = 2) n°28,49RBANSRepeatable Battery for Assessment of Neuropsychological Status(*n* = 1) n°8Symbol digit(*n* = 3) n°16,43,46Trail Making Test(*n* = 4) n°3,4,19,30Verbal fluency(*n* = 12) n°3,9,11,19,25,30,35,37,38,43,46,49LanguageBNTBoston Naming Test(*n* = 5) n°3,25,30,37,46COWAControlled Oral Word Association(*n* = 4) n°1,3,4,11FASLetter-Number Sequencing and Phonemic verbal fluency(*n* = 2) n°11,25Naming(*n* = 1) n°49NARTAmerican National Adult Reading test(*n* = 2) n°3,46WAISWechlser Adult Intelligence Scale(*n* = 6) n°3,4,9,11,19,30MemoryBIMCBlessed Information Memory Concentration(*n* = 2) n°6,19FCSRTFree and Cue Selective Reminding Test(*n* = 2) n°3,19FOMEFuld Object Memory Evaluation(*n* = 1) n°19HVLTHopkins Verbal Learning test(*n* = 3) n°11,25,43Memory(*n* = 5) n°3,16,35,46,53RAVLTRey auditory verbal learning test(*n* = 3) n°1,4,30Recall(*n* = 2) n°46,49WMSWechsler Memory Scale(*n* = 2) n°9,30Visual-spatialBVRTBenton Visual Retention Test(*n* = 1) n°9CPM*Raven's coloured progressive matrices*(*n* = 2) n°19,46JLOBenton Judgement Line Orientation(*n* = 4) n°4,25,43,46Orientation(*n* = 1) n°53PARRPicture Arrangement subtest(*n* = 1) n°9ROCFRey-Osterrieth Complex Figure test recall(*n* = 1) n°11Visual attention(*n* = 1) n°19Unknown(*n* = 1) n°15Psychiatric symptoms (*n* = 38)Depression / AnxietyASApathy Evaluation Scale(*n* = 3) n°4,32,33BAIBeck Anxiety Inventory(*n* = 4) n°18,30,33,44BDIBeck Depression Inventory(*n* = 9) n°5,11,18,26,30,32,33,36,44CESD-10Center for Epidemiological Studies Depression Scale(*n* = 3) n°24,39,47GDSGeriatric Depression Screening scale(*n* = 17) n°1,3,4,5,7,8,10,14,20,25,26,28,34,40,43,48,50HAM-AHamilton Anxiety Rating Scale(*n* = 2) n°33,40HDRSHamilton Depression Rating Scale(*n* = 3) n°4,15,33LeedsLeeds anxiety and depression scale(*n* = 1) n°38SCIDStructured Clinical Interview - Depression(*n* = 2) n°28,40STAIState Trait Anxiety Inventory(*n* = 4) n°18,24,39,43UPDRS-IUnified Parkinson's Disease Rating Scale - mentation behavior and mood(*n* = 7) n°1,14,17,25,27,43,52ZUNGZung depression scale(*n* = 1) n°19TOCOCI-RObsessive-Compulsive Inventory -- Revised(*n* = 1) n°18QUIPQuestionnaire for impulsive-compulsive disorders in parkinson's disease-rating scale(*n* = 2) n°40,43YBOCSYale-Brown obsessive-compulsive scale(*n* = 1) n°33OtherCoNegcomposite negative score(*n* = 1) n°29MMPIMultiphasic Personality Inventory(*n* = 1) n°29NPINeuroPsychiatric Inventory questionnaire(*n* = 3) n°1,34,47QABBQuestionnaire About Buying Behaviour(*n* = 1) n°40RushRush Hallucination Inventory(*n* = 1) n°21SCSSexual Compulsivity Scale(*n* = 1) n°40YMRSYoung Mania Rating Scale(*n* = 1) n°33Unknown(*n* = 4) n°6,15,46,49Activities of daily living (*n* = 22)ACSActivity Card Sort(*n* = 1) n°20ADCS-ADLAlzheimer's Disease Cooperative Study ADL Inventory(*n* = 1) n°25IADLKatz Instrumental Activity of Daily Living(*n* = 2) n°46,47S&ESchwab & England activities of daily living scale(*n* = 10) n°5,14,18,26,34,38,41,43,44,53UPDRS-IIUnified Parkinson's Disease Rating Scale - self-evaluation of the activities of daily living(*n* = 9) n°1,5,11,14,26,27,40,43,52Unknown(*n* = 3) n°15,17,51Sleep quality (*n* = 11)Actigraphy(*n* = 1) n°47ESSEpworth Sleepiness Scale(*n* = 4) n°5,14,38,43FSSFatigue Severity Scale(*n* = 1) n°40ISIInsomnia Severity Index(*n* = 1) n°40MSQMayo clinic Sleep Questionnaire(*n* = 2) n°4,30PDSSParkinson's disease sleep scale(*n* = 1) n°40PSQIPittsburg Sleep Quality Index(*n* = 2) n°21,40RBDSQREM Sleep Behaviour Disorder Screening Questionnaire(*n* = 2) n°38,43SA-SDQSleep Apnea Scale of Sleep Disorders Questionnaire(*n* = 1) n°40SSSStanford Sleepiness Scale(*n* = 1) n°40Unknown(*n* = 2) n°15,24Quality of life (n = 9)EQ-5DEuro Quality of Life 5 Dimension questionnaire(*n* = 2) n°14,38Neuro-QOLQuality of Life in Neurological Disorders(*n* = 1) n°34NHPNottingham Health Profile(*n* = 1) n°20PDQUALIFParkinson's Disease Quality of Life Scale(*n* = 3) n°14,18,40PDQ-3939-item Parkinson's disease quality of life(*n* = 5) n°7,10,20,35,40PIMSParkinson's Impact Scale(*n* = 1) n°40SF-12The 12 item Short Form health survey(*n* = 2) n°14,20SF-36The 36 item Short Form health survey(*n* = 1) n°40SWAL-QOLSwallow-specific quality of life(*n* = 1) n°40Autonomic symptoms (n = 7)Bowel movement(*n* = 1) n°24COMPASSComposite autonomic symptom Scale(*n* = 1) n°40SCOPA-AUTScales for outcomes of Parkinson's Disease -- autonomic symptoms(*n* = 3) n°4,5,43Unknown(*n* = 2) n°15,30Other (*n* = 20)OlfactionBrief-SITBrief Smell Identification Test(*n* = 2) n°24,4716-item sniffin' Sticks Odour Identification test(*n* = 1) n°38UPSITUniversity of Pennsylvania Smell Identification Test(*n* = 6) n°1,4,5,34,39,43Restless legs syndromeCH-RLSQCambridge-Hopkins Restless Legs Syndrome Diagnostic Questionnaire(*n* = 1) n°40IRLSSGInstrument for the Assessment of Restless Legs Syndrome Severity(*n* = 1) n°4CaregiverCSIcaregiver strain index(*n* = 1) n°35deJong-Gierveld Loneliness Scale(*n* = 1) n°47MCSIMultidimensional Caregiver Strain Index(*n* = 1) n°35Caregiver interview(*n* = 1) n°21OtherAgonal state questionnaire(*n* = 1) n°51CGIClinical Global Impression scale(*n* = 1) n°38CIRSChronic Illness Resource Survey(*n* = 1) n°20GHSGlobal Health Score(*n* = 1) n°8GISGlobal Impression Scale(*n* = 1) n°51Howard-Dohlman device(*n* = 1) n°48MNA*Mini Nutritional Assessment*(*n* = 1) n°40MOS*Medical outcome study*(*n* = 1) n°20MSSSSMedical Outcomes Study Social Support Scale(*n* = 1) n°28Pain(*n* = 1) n°40PASEPhysical Activity Scale for the Elderly(*n* = 3) n°7,10,43SRRSSocial Readjustment Rating scale(*n* = 1) n°28SSCIStigma Scale for Chronic Illness(*n* = 1) n°20Tremor rating(*n* = 1) n°4Visual acuity(*n* = 1) n°48Unknown(*n* = 1) n°15

Most sources assessed motor and neurological functions (87%), cognition (77%) and psychiatric symptoms (72%). Activity level (42%), sleep quality (21%), quality of life (17%) and autonomic symptoms (13%) were reported to a lesser extent. The most commonly measurements used to assess motor and neurological symptoms were the Unified Parkinson's Disease Rating Scale part III (UPDRS-III, 77% of included data sources) and the Hoehn and Yahr scale (H&Y, 57% of included data sources)(Table [4](#Tab4){ref-type="table"}). To evaluate the cognitive impairment, the Mini Mental State Examination (MMSE, 57%) was the most frequent. Those most frequently used to assess psychiatric symptoms were the Geriatric Depression Scale (GDS, 32%) and Beck Depression Inventory (BDI, 15%). For the other dimensions, the most commonly used measurements were: the Epworth Sleepiness Scale (ESS, 8%, for sleep), the Schwab and England (S&E, 19%, for activities of daily living), the 39-item Parkinson's disease Quality of life (PDQ-39, 9%, for the quality of life) and the autonomic part of the Scales for outcomes of Parkinson's disease (SCOPA-AUT, 6%, for autonomic symptoms). In absolute frequency, the use of ESS, PDQ-39 and SCOPA-AUT is very low, even if they were the most frequently used measurements in their dimension.

The analysis reveals some interesting differences between sources on the number of measurements applied by dimension. Some sources evaluate only one dimension (source n°13) when others evaluate seven dimensions (source n°43). Completed sources have more frequent measurements of motor and neurological symptoms (92% vs 75%), psychiatric symptoms (76% vs 63%) and activities of daily living (43% vs 38%) than ongoing sources. US sources evaluate more frequently the cognitive impairment then international sources (86% vs 45%) but less frequently all the other dimensions. "Generic" sources evaluate three dimensions more frequently than specific sources including only Parkinsonian patients: cognition (86% vs 68%), sleep (32% vs 8%) and autonomic symptoms (25% vs 0%).

Lastly, the frequencies of these assessments are dependent on the primary objective of the sources but with an important overlap: 100% of the sources investigating motor symptoms used measurements of motor symptoms and mainly the UPDRS-III, but they also frequently assessed cognition (88%), sleep (25%) and quality of life (25%). The sources investigating non-motor symptoms frequently assessed cognition (82%), psychiatric symptoms (88%) most of the time with, respectively, the GDS (41%) and the MMSE (65%). The two genetic sources have several patient reported outcomes and they both measured motor and psychiatric symptoms.

Some measurements were used more often for some above-mentioned objectives. While the GDS and the UPDRS-III were used specifically in sources investigating, respectively, the non-motor symptoms and the motor symptoms as a primary objective, the BDI and the H&Y were used in sources investigating the other objectives.

Discussion {#Sec10}
==========

A large number of longitudinal real world data sources for PD have been identified. There is no consistency of the dimensions assessed, nor of the measurements used across sources, reflecting the absence of harmonization on the optimal choice of measurements.

There are a number of issues with collecting real world data such as limited size of the databases \[[@CR1]\], inability to accurately determine specific outcomes \[[@CR62]\], and more chance of bias and confounding factors \[[@CR5]\]. Nevertheless, they have an important role to play in the evaluation of epidemiology, burden of disease and treatments patterns \[[@CR6]\]; and in assisting health-care decision-makers, especially related to coverage and payment decisions \[[@CR63]\]. In this context, a harmonization seems necessary. These results are quite consistent with those observed in Europe where a "consensus on domains incorporated in different studies \[was observed\] with a substantial variability in the choice of the evaluation method" \[[@CR4]\]. There are a number of possible explanations for this absence of harmonization and some of them are discussed here.

First of all, some dimensions are broad. In consequence many measurements are available according to each source objective, design and population. This heterogeneity probably reflects both the absence of harmonization and the complexity of the evaluation of a dimension like cognition \[[@CR64]\]. A single measurement cannot assess all necessary information. For example, the combination of patient reported outcomes and medical reported outcomes can be very informative and complement one another. In a consistent manner, the combination of Parkinson specific and generic measurements can be a necessity especially for "generic" data sources including not only Parkinsonian patients. In another example, while the objectives of the UPDRS-III and the H&Y (or of the GDS and the BDI) are close, the difference of their use according to the study primary objective of the source seems more linked to the investigator choice than to the suitability of the measurement.

Secondly, PD is characterized by several initial system disorders and treatment complications \[[@CR65]\]. To date, motor subtyping has dominated the landscape of PD research but non-motor dimensions evaluations are increasing \[[@CR9], [@CR66]\], and thus the number of dimensions to evaluate. For non-motor dimensions, some have validated measurements such as psychiatry \[[@CR67]\], activity disability \[[@CR7]\], sleep \[[@CR68]\] or quality of life \[[@CR69]\]; but others have no clear review of validated and used scales \[[@CR4]\]. Among the psychiatric scales, the two most frequently used were the GDS and the BDI. This finding highlights the well-known relationship between PD and depression, and the fact that when validated scales \[[@CR70]\] are available, a harmonization of practice is observed. The lack of evaluation and validation of the measurements in PD is probably partly a source of such an heterogeneity.

Thirdly, clinical research purposes and outcomes are in permanent evolution over time \[[@CR71], [@CR72]\], as highlighted by the many differences between completed and ongoing sources. New trends are not well covered right now, either due to lack of measurements or due to lack of capture (i.e. utilization of available measurements in databases). Among the most important of those are the genetic testing, the caregiver burden and the costs. The important development of genetic testing has come in the last few years, with an increase of the mutations and treatment discoveries such as LRRK2 and its kinase inhibitors. But research is necessary to understand the role of genetic mutations in PD \[[@CR73]\]. Sources based on caregiver burden and relevant validated measurements are very limited \[[@CR7]\]. But the interest for these data is growing with the recognition of their physical, emotional and economic burden \[[@CR74]\]. The only data source identified as measuring healthcare costs associated with PD was ongoing. It probably reflects both the recent growing interest of health economic evaluation and the fact that this type of study is more often conducted in automated healthcare databases \[[@CR75]\].

Fourthly, there is a possible improvement of the access to the data source details. Given information is fragmented between different sources of information and study protocols or outcomes lists are not always available. In consequence identifying and gathering this information to produce an integrated view can be really difficult.

Finally, the variability of our results is greater than in the European study. This may be because the classification is based on dimensions assessing mostly symptoms, 5 out of 8 dimensions. This classification probably more appropriate for data sources with a primary objective of treatment evaluation (e.g. open-label extension), which are a minority of the included sources. The classification may not be as applicable to assess other data sources focused on the evaluation of burden. Real world evidence collection is done for various purposes and such a restricted classification can lead to ambiguous conclusions. It can lead to a perception of consensus while actually missing important aspects such as burden, function or complications of treatments.

Our study has several limitations. First of all, only one reader has conducted the record selection and the data extraction unlike systematic reviews. Nevertheless, the search methods identified a large number of PD data sources for extraction and comparison. No contact was established with investigators of the included studies to confirm data extraction results. To address this issue, a second step has been performed after the data extraction from the publications, to update and complete the published information with all other available sources. At risk/prodromal cohorts have not been separated from clinical PD cohorts, but the distinction between these two subgroups has recently been described as artificial \[[@CR4]\].

Our study has several strengths. It is the first review of existing real world longitudinal data sources on PD in USA to our knowledge. Moreover, it was performed with broad research criteria and without any limitation on language, type of publication or type of measurements. This review creates an integrated view and should assist investigators and clinicians to identify and optimize the measurements that best match with their objectives and the already existing data sources.

Conclusion {#Sec11}
==========

In conclusion, many longitudinal real world data sources on PD exist. Different types of measurements have been used over time. To allow comparison and pooling of these multiple data sources, it will be essential to harmonize practices in terms of types of measurements.

Appendix 1 {#Sec12}
==========

Search strategy.

Equation 1: Disease selection

(EMB.EXACT("Parkinson disease") OR MESH.EXACT("Parkinson Disease") OR ab("Parkinson\*")

OR ti("Parkinson\*") OR EMB.EXACT("antiparkinson agent") OR MESH.EXACT("Antiparkinson Agents")) AND (human(yes) AND human(yes)).

Equation 2: Disease exclusion

(MESH.EXACT("Parkinson Disease, Postencephalitic") OR MESH.EXACT("Parkinson Disease, Secondary") OR EMB.EXACT("Wolff Parkinson White syndrome") OR EMB.EXACT("experimental parkinsonism") OR EMB.EXACT("parkinsonism") OR EMB.EXACT("MPTPinduced parkinsonism")) AND (human(yes) AND human(yes))

Equation 3: Study type selection

((EMB.EXACT("register") OR EMB.EXACT("long term care") OR EMB.EXACT("retrospective study") OR EMB.EXACT("prospective study") OR EMB.EXACT("cohort analysis") OR EMB.EXACT("clinical practice") OR EMB.EXACT("longitudinal study")) OR (MESH.EXACT("Cohort Studies") OR MESH.EXACT("Registries") OR MESH.EXACT("Longitudinal Studies") OR MESH.EXACT("Long-Term Care") OR MESH.EXACT ("Retrospective Studies") OR MESH.EXACT("Prospective Studies") OR MESH.EXACT("Practice Patterns, Physicians'"))) OR (((longitudinal OR retrospective OR prospective OR cohort OR "follow up" OR observational OR naturalistic OR "cross\*sectional" OR epidemio\* OR database) NEAR/1 (study OR studies)) OR "cohort analysis" OR "registry" OR "register\*" OR "real-world" OR "treatment pattern\*" OR "survey\*" OR "medical records" OR "population-correlation" OR "population-based" OR "population-level")

Equation 4: Study type exclusion

((MESH.EXACT("Case-Control Studies") OR MESH.EXACT("Controlled Before-After Studies") OR.

MESH.EXACT("Feasibility Studies") OR MESH.EXACT("Clinical Trial") OR MESH.EXACT("Organizational Case Studies") OR MESH.EXACT("Evaluation Studies")) OR (EMB.EXACT ("major clinical study") OR EMB.EXACT("in vivo study") OR EMB.EXACT("evaluation study") OR EMB.EXACT("in vitro study") OR EMB.EXACT("first in human study") OR EMB.EXACT("experimental study") OR EMB.EXACT("case study") OR EMB.EXACT("clinical study") OR EMB.EXACT("intervention study") OR EMB.EXACT("case control study"))).

Equation 5: Combination of the previous equation

(Equation 1 NOT Eq. 2) AND (Eq. 3 NOT Eq. 4)

Equation 6: Country selection

GI("United States\*") OR ti("America\*") OR ab("America \*") OR ab("usa") OR ti("usa") OR ab("us") OR ti("us") OR ab("u.s") OR ti("u.s").

Equation 7: Application of the combination equation to the country of interest

Equation 6 AND Eq. 6

Appendix 2 {#Sec13}
==========

List of outcomes extracted.

Acronym

○Full name

○Country (−ies)

○Database size (total number of patients and number of Parkinsonian patients)

○Database type

○Name of investigator (corresponding author of the publication, reference person)

○Funder(s)

○Medical imaging

○Scales list

○Scales dimension 1: Activities of daily living

○Scales dimension 2: Cognition

○Scales dimension 3: Motor or neurologic symptoms

○Scales dimension 4: Psychiatric symptoms

○Scales dimension 5: Sleep quality

○Scales dimension 6: Quality of life

○Scales dimension 7: Autonomic symptoms

○Scales dimension 8: Other

○Healthcare costs

○Genetics

○Comorbidities

○Current medications

○Severity of disease

○Caregiver burden

○Date of beginning of the study

○Date of end of the study

○Duration of follow-up

○Planned follow-ups

○Particular inclusion criteria

BDI

:   Beck Depression Inventory

ESS

:   Epworth Sleepiness Scale

FDA

:   Food and Drug Administration

GDS

:   Geriatric Depression Scale

H&Y

:   Hoehn and Yahr scale

MMSE

:   Mini Mental State Examination

PD

:   Parkinson's disease

PDQ-39

:   39-item Parkinson's disease Quality of life

S&E

:   Schwab and England

SCOPA-AUT

:   autonomic part of the Scales for outcomes of Parkinson's disease

UPDRS-III

:   Unified Parkinson's Disease Rating Scale part III

USA

:   United States of America
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